GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Price-to-Funds-From-Operations

SCYNEXIS (LTS:0L49) Price-to-Funds-From-Operations : (As of May. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


SCYNEXIS (LTS:0L49) Business Description

Industry
Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.